The Patient-Centered Outcomes Research Institute (PCORI) today announced $37 million in funding awards through its Health Systems Implementation Initiative (HSII). These awards will support 25 projects implementing PCORI-funded comparative clinical effectiveness research (CER) findings in participating HSII health systems.
Case Western Reserve University School of Medicine identifies a potential new approach to address the opioid overdose epidemic鈥攚hich has devastated families and communities nationally. Semaglutide was found to lower opioid overdoses in people with opioid-use disorder (OUD) and type 2 diabetes (T2D).
Mount Sinai Health System, a leading health system in the United States and one of the largest in the New York City area, and Noom, the leading digital health care company committed to chronic disease prevention and empowering people to live better and healthier lives, have partnered to provide patients with a whole-person approach to healthy, long-lasting weight loss.
Scientists from Immanuel Kant Baltic Federal University analyzed scientific works dedicated to the role of proteins prohibitins in the development of obesity. It turned out that these proteins promote development of inflammation both in separate cells and the whole organism. This happens because prohibitins stimulate emission of anti-inflammatory substances by immune cells, and also participate in destruction of mitochondria damaged during oxidative stress. Obtained information points to the fact that prohibitins can become targets for medicine aimed at struggle with obesity consequences. Results of the research are published in the magazine Frontiers in Molecular Biosciences.
Wegovy (semaglutide) now has Medicare approval for coverage among people with obesity and cardiovascular disease but no diabetes; a study looks at what level of risk might make someone eligible.
To promote high-quality, person-directed care across the spectrum of kidney health and diseases the American Society of Nephrology (ASN) is releasing its inaugural Kidney Health Guidance (KHG) on the Management of Obesity in Persons Living with Kidney Diseases in the Journal of the American Society of Nephrology (JASN) on September 18, 2024.
Participating in a high volume of exercise over a short period of time, such as cycling hundreds of miles in a few days, could reduce body fat levels without weight loss. The first-of-its-kind study is published ahead of print in the American Journal of Physiology-Endocrinology and Metabolism and has been chosen as an APSselect article for September.
A new national survey from The Ohio State University Wexner Medical Center reveals 1 in 4 (25%) of 1,006 adults surveyed would consider using an injectable weight loss medication without consulting their doctor.
Since anti-obesity medications have become more widely known and prescribed, they have been touted as game-changing treatments for chronic overweight and obesity. But one common misconception about these medications is that they鈥檙e a magic bullet for better health, and it doesn鈥檛 necessarily matter what you eat when you鈥檙e taking them.
Primary care providers are well positioned to address emotional eating because of their long-term relationships with patients, noted Jana DeSimone Wozniak, PhD and Hsiang Huang, MD, MPH, of Harvard Medical School and Cambridge Health Alliance in Cambridge, Massachusetts.
Popular ideas about weight loss often aren鈥檛 based in science and can actively harm your health. Here are some of the most common myths, along with some tips to improve your health sustainably while maintaining a healthy attitude toward weight and food.
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that patient dosing has started for the clinical study entitled: BMT-801: A Phase II, Randomized, Double-Blind, Placebo-Controlled, Clinical Study Investigating the Safety, Tolerability, and Effectiveness of the Co-Administration of Bremelanotide with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity (ClinicalTrials.gov Identifier: NCT06565611).
Drugs such as Ozempic, Rybelsus and Wegovy have made news for their abilities to treat diabetes and encourage weight loss. To give a clearer understanding of the benefits and risks of GLP-1 agonists for patients with liver disease, Robert Fontana, M.D.,鈥痑 Michigan Medicine hepatologist, answered our questions.
New research finds a combination of drugs improves weight loss, glucose control and insulin resistance better than either drug alone. Using two diabetes medications together, such as a semaglutide like Ozempic or Rybelsus, with a second, newer class of drug, may offer a noninvasive solution to help people with Type 2 diabetes lose weight and manage their condition without the need for bariatric surgery.
A new class of medications called GLP-1s (glucagon-like peptide-1 receptor agonists) have been grabbing headlines for their dramatic results in helping people shed stubborn pounds, thereby controlling diabetes as well as reducing their risk of heart disease.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal 欧美极品 keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
